ADEL-001

ADEL-001 is an RNA aptamer drug candidate developed by Aptadel Therapeutics. It functions as a modulator of Ephrin type-A receptor 2 (EphA2), a receptor tyrosine kinase implicated in tumor growth and metastasis. The drug is designed to inhibit metastatic potential in various cancer types, including neoplasm metastasis, by specifically targeting the EphA2 receptor on tumor cells. As an aptamer-based therapy, ADEL-001 offers high target affinity and specificity with low immunogenicity and toxicity, aiming for effective tissue penetration and cost-effective manufacturing. Its current development status is preclinical[1][7].